Skip to content
  • Reports
  • Podcast Subscribe
  • Log In

Now covering the global biotech industry!
Read More
Topics
  • CRISPR
  • CAR-T
  • Covid-19
  • Microbiome
  • mRNA technology
  • Gene therapy
  • CRISPR
  • CAR-T
  • Covid-19
  • Microbiome
  • mRNA technology
  • Gene therapy
  • Log In
Now covering the global biotech industry!
Read More

Home » What’s new » Circassia

Circassia

ADVERTISEMENT
News and Trends

ASIT Biotech Raises €13.9 M to Develop Allergy Immunotherapies

ASIT Biotech, a Belgian company specialized in allergy immunotherapy, raised a total of €13.9M to…

By Alexander Burik
February 26, 2018 - 3 minutes
News and Trends

Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success

Circassia has positive Phase III results from its respiratory pipeline, great news for the company…

By Clara Rodríguez Fernández
September 7, 2017 - 2 minutes
News and Trends

Circassia Freezes its Allergy Portfolio after a Second Failed Clinical Trial

Circassia Pharmaceuticals will stop investing in its allergy programs due to two failed clinical trials…

By Clara Rodríguez Fernández
April 18, 2017 - 2 minutes
News and Trends

Can this British Biotech Overcome Failure buying drugs from AstraZeneca?

After the big disaster with its cat allergy vaccine, Circassia closes a €214M deal to…

By Clara Rodríguez Fernández
March 17, 2017 - 2 minutes
News and Trends

The 8 Biggest Biotech Medical Fails of 2016 in Europe

Although 2016 has brought plenty of good news in medical advances, biotech is an industry…

By Clara Rodríguez Fernández
December 23, 2016 - 5 minutes
News and Trends

June was a Tough Month for European Biotech… #Fail

Abivax, Celyad, Circassia and Genticel - these are all European Biotechs that took a hit…

By Denise Neves Gameiro
July 6, 2016 - 3 minutes
News and Trends

Allergy Immunotherapy Knocked Out in Phase III by an ‘Overperforming Placebo’

Circassia's pipeline takes a major step back as its therapy for cat allergy gets disappointing…

By Denise Neves Gameiro
June 21, 2016 - 3 minutes
News and Trends

UK Immunotherapy against Grass Allergies moves on to Phase III Trials

Circassia is beginning a Phase III trial for its short-course immunotherapy for grass allergies. This…

By Denise Neves Gameiro
May 31, 2016 - 2 minutes
News and Trends

It’s raining cash, Woodford invested more than 75% of its mega €1.1Bn Biotech fund

Cash is floating into Biotech like never before, in the US as well as in…

By Philip Hemme
August 14, 2015 - 2 minutes
News and Trends

2014, the Biggest Year Ever for European Biotech IPOs

There is no need to say it: biotechnology is the latest trend. A worldwide bio-boom…

By Lourdes Riquelme
February 6, 2015 - 3 minutes
footer logo

Labiotech.eu is the leading digital media covering the global biotech industry.

Over 150,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you’ll enjoy reading our stories!

  • About us
  • Inside Labiotech
  • Join Us
  • Advertise
  • Contact
  • Editorial Calendar
  • Site Map
  • Linkedin
  • Twitter
  • Youtube
  • RSS Feed
Made with in Berlin. Labiotech UG, All Rights Reserved -
  • Imprint
  • Privacy Policy

Browse Topics

Search for a topic, country or company name by using the search box

    Popular topics:


    CRISPR mRNA technology CAR-T HIV Cell therapy Diabetes Microbiome Gene therapy Synthetic biology
    Labiotech.eu
    • Log In

    Topics

    • Gene Therapy
    • CRISPR
    • CAR-T
    • Covid-19
    • Microbiome
    • Diabetes
    • Cancer

    Sections

    • News and Trends
    • In Depth
    • Best in Biotech
    • Opinion
    • Interview
    • Infographics
    Show All Topics

    For Members

    • Expert Advice
    • Reports
    • Startup Scout

    More

    • About us
    • Inside Labiotech
    • Join Us
    • Advertise
    • Contact
    • Podcast
    • Biotech Events
    • Awareness Days